Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD study of Aneratrigine mesilate in healthy volunteers
NCT05496205Phase 1Completed
- Sponsor
- iN Therapeutics
- Start
- Sep 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of iN1011-N17 in osteoarthritis (OA), pain, postherpetic neuralgia (PHN) and 2 more (4 arms), sponsored by iN Therapeutics. Primary endpoints: Adverse Events, Abnormal Physical Examination Findings at Day 8 and 7 more. Started Sep 2020; status: completed.
02
Drugs
iN1011-N17
03
Conditions
osteoarthritis (OA)painpostherpetic neuralgia (PHN)neuropathic painchronic pain
Beyond the preview
Go deeper on NCT05496205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05496205.